Abstract
Adenoviral vector-mediated gene delivery has been vastly investigated for cystic fibrosis (CF) gene therapy; however, one of its drawbacks is the low efficiency of gene transfer, which is due to basolateral colocalization of viral receptors, immune responses to viral vectors and the presence of a thick mucus layer in the airways of CF patients. Therefore, enhancement of gene transfer can lead to reduction in the viral dosage, which could further reduce the acute toxicity associated with the use of adenoviral vectors. Nacystelyn (NAL) is a mucolytic agent with anti-inflammatory and antioxidant properties, and has been used clinically in CF patients to reduce mucus viscosity in the airways. In this study, we show that pretreatment of the airways with NAL followed by administration of adenoviral vectors in complex with DEAE-Dextran can significantly enhance gene delivery to the airways of mice without any harmful effects. Moreover, NAL pretreatment can reduce the airway inflammation, which is normally observed after delivery of adenoviral particles. Taken together, these results indicate that NAL pretreatment followed by adenoviral vector-mediated gene delivery can be beneficial to CF patients by increasing the efficiency of gene transfer to the airways, and reducing the acute toxicity associated with the administration of adenoviral vectors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Koehler DR, Downey GP, Sweezey NB, Tanswell AK, Hu J . Lung inflammation as a therapeutic target in cystic fibrosis. Am J Respir Cell Mol Biol 2004; 31: 377–381.
Grubb BR, Pickles RJ, Ye H, Yankaskas JR, Vick RN, Engelhardt JF et al. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 1994; 371: 802–806.
Sanders NN, De Smedt SC, Van Rompaey E, Simoens P, De Baets F, Demeester J . Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am J Respir Crit Care Med 2000; 162: 1905–1911.
Vanderbist F, Wery B, Baran D, Van Gansbeke B, Schoutens A, Moes AJ . Deposition of nacystelyn from a dry powder inhaler in healthy volunteers and cystic fibrosis patients. Drug Dev Ind Pharm 2001; 27: 205–212.
Vanderbist F, Wery B, Moyano-Pavon I, Moes AJ . Optimization of a dry powder inhaler formulation of nacystelyn, a new mucoactive agent. J Pharm Pharmacol 1999; 51: 1229–1234.
Gillissen A, Jaworska M, Orth M, Coffiner M, Maes P, App EM et al. Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Respir Med 1997; 91: 159–168.
Tomkiewicz RP, App EM, Coffiner M, Fossion J, Maes P, King M . Mucolytic treatment with N-acetylcysteine L-lysinate metered dose inhaler in dogs: airway epithelial function changes. Eur Respir J 1994; 7: 81–87.
Tomkiewicz RP, App EM, De Sanctis GT, Coffiner M, Maes P, Rubin BK et al. A comparison of a new mucolytic N-acetylcysteine L-lysinate with N-acetylcysteine: airway epithelial function and mucus changes in dog. Pulm Pharmacol 1995; 8: 259–265.
Dasgupta B, King M . Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase. Pediatr Pulmonol 1996; 22: 161–166.
App EM, Baran D, Dab I, Malfroot A, Coffiner M, Vanderbist F et al. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis. Eur Respir J 2002; 19: 294–302.
Nagy AM, Vanderbist F, Parij N, Maes P, Fondu P, Neve J . Effect of the mucoactive drug nacystelyn on the respiratory burst of human blood polymorphonuclear neutrophils. Pulm Pharmacol Ther 1997; 10: 287–292.
Vosters O, Neve J, De Wit D, Willems F, Goldman M, Verhasselt V . Dendritic cells exposed to nacystelyn are refractory to maturation and promote the emergence of alloreactive regulatory t cells. Transplantation 2003; 75: 383–389.
Ferrari S, Kitson C, Farley R, Steel R, Marriott C, Parkins DA et al. Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium. Gene Therapy 2001; 8: 1380–1386.
Stern M, Caplen NJ, Browning JE, Griesenbach U, Sorgi F, Huang L et al. The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro. Gene Therapy 1998; 5: 91–98.
Antonicelli F, Parmentier M, Drost EM, Hirani N, Rahman I, Donaldson K et al. Nacystelyn inhibits oxidant-mediated interleukin-8 expression and NF-kappaB nuclear binding in alveolar epithelial cells. Free Radic Biol Med 2002; 32: 492–502.
Antonicelli F, Brown D, Parmentier M, Drost EM, Hirani N, Rahman I et al. Regulation of LPS-mediated inflammation in vivo and in vitro by the thiol antioxidant Nacystelyn. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1319–L1327.
Gregory LG, Harbottle RP, Lawrence L, Knapton HJ, Themis M, Coutelle C . Enhancement of adenovirus-mediated gene transfer to the airways by DEAE dextran and sodium caprate in vivo. Mol Ther 2003; 7: 19–26.
Kaplan JM, Pennington SE, St George JA, Woodworth LA, Fasbender A, Marshall J et al. Potentiation of gene transfer to the mouse lung by complexes of adenovirus vector and polycations improves therapeutic potential. Hum Gene Ther 1998; 9: 1469–1479.
Marsman WA, Buskens CJ, Wesseling JG, Van Lanschot JJ, Bosma PJ . Gene therapy for barrett's esophagus: adenoviral gene transfer in different intestinal models. Cancer Gene Ther 2005; 12: 778–786.
Pupita F, Barone A . Clinical pharmacology of DEAE-dextran for long-term administration (one year). Int J Clin Pharmacol Res 1983; 3: 287–293.
Koehler DR, Sajjan U, Chow YH, Martin B, Kent G, Tanswell AK et al. Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia. Proc Natl Acad Sci USA 2003; 100: 15364–15369.
Fehrenbach H . Animal models of chronic obstructive pulmonary disease: some critical remarks. Pathobiology 2002; 70: 277–283.
Chow YH, Plumb J, Wen Y, Steer BM, Lu Z, Buchwald M et al. Targeting transgene expression to airway epithelia and submucosal glands, prominent sites of human CFTR expression. Mol Ther 2000; 2: 359–367.
Koehler DR, Martin B, Corey M, Palmer D, Ng P, Tanswell AK et al. Readministration of helper-dependent adenovirus to mouse lung. Gene Therapy 2006; 13: 773–780.
Acknowledgements
We gratefully acknowledge Cathleen Duan for assistance in performing β-galactosidase assays, and Dr Colin McKerlie (Hospital for Sick Children, Toronto, Canada) for assistance in histological assessment of inflammation in the mouse airways. This work was supported by Operating Grants from the Canadian Institutes of Health Research, the Canadian Cystic Fibrosis Foundation and the Foundation Fighting Blindness-Canada. J Hu is a CCFF Scholar and recipient of the CCFF Zellers Senior Scientist Award, and holds a Premier's Research Excellence Award of Ontario, Canada.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kushwah, R., Oliver, J., Cao, H. et al. Nacystelyn enhances adenoviral vector-mediated gene delivery to mouse airways. Gene Ther 14, 1243–1248 (2007). https://doi.org/10.1038/sj.gt.3302968
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302968
Keywords
This article is cited by
-
Potential of helper-dependent Adenoviral vectors in CRISPR-cas9-mediated lung gene therapy
Cell & Bioscience (2021)
-
Epithelium-specific Ets transcription factor-1 acts as a negative regulator of cyclooxygenase-2 in human rheumatoid arthritis synovial fibroblasts
Cell & Bioscience (2016)
-
Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review
European Journal of Clinical Microbiology & Infectious Diseases (2013)
-
Advances in Cell and Gene-based Therapies for Cystic Fibrosis Lung Disease
Molecular Therapy (2012)
-
Jaagsiekte sheep retrovirus pseudotyped lentiviral vector-mediated gene transfer to fetal ovine lung
Gene Therapy (2012)